Skip to main content
Shenogen signs cancer combo deal with Lee's Pharma

Shenogen Pharma agreed to collaborate with Lee's Pharmaceutical to develop and market in China the combination of Lee's ZKAB001 and Shenogen's icaritin for the treatment of late-stage cancers. Shenogen is conducting a Phase III trial of icaritin in hepatocellular carcinoma patients.

Full Story: